ANDA User Fee Misses Are Mostly Part Of 'Imminent Approval' Process
Executive Summary
US FDA will miss goal dates to reach speedier generic drug application approvals, but says decisions will be case by case.
You may also be interested in...
ANDA Reviews Sometimes Miss GDUFA Goal Dates To Get Quicker Approval, But How Often?
Preliminary performance data suggests only a handful of applications receiving US FDA action by the end of FY 2018 actually missed their review goals.
US FDA Generic Approvals Break 900 Barrier In FY 2019
The record number of full ANDA approvals also exceeded submissions for the first time since GDUFA was enacted.
US FDA May Start Missing ANDA User Fee Goals – In Order To Speed Approvals
Agency will work past generic goal dates if approval can be achieved quickly thereafter, but now must create policy defining criteria for those situations.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available Buy Reports
Need a specific report? 1000+ reports available Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: